Zai Lab (ZLAB) Competitors $35.40 -0.27 (-0.76%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$35.20 -0.20 (-0.56%) As of 03/25/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZLAB vs. SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, and QGENShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Summit Therapeutics Intra-Cellular Therapies Genmab A/S Moderna Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Sarepta Therapeutics Vaxcyte Qiagen Summit Therapeutics (NASDAQ:SMMT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Does the media refer more to SMMT or ZLAB? In the previous week, Summit Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for Summit Therapeutics and 9 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.21 beat Summit Therapeutics' score of 0.68 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in SMMT or ZLAB? Summit Therapeutics received 77 more outperform votes than Zai Lab when rated by MarketBeat users. However, 64.43% of users gave Zai Lab an outperform vote while only 58.48% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30758.48% Underperform Votes21841.52% Zai LabOutperform Votes23064.43% Underperform Votes12735.57% Which has more volatility and risk, SMMT or ZLAB? Summit Therapeutics has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Which has stronger valuation & earnings, SMMT or ZLAB? Zai Lab has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K21,329.49-$614.93M-$0.31-65.29Zai Lab$398.99M9.73-$334.62M-$2.59-13.67 Do analysts rate SMMT or ZLAB? Summit Therapeutics currently has a consensus price target of $34.11, indicating a potential upside of 68.53%. Zai Lab has a consensus price target of $47.37, indicating a potential upside of 33.80%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Zai Lab 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SMMT or ZLAB more profitable? Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -76.14%. Zai Lab's return on equity of -36.97% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Zai Lab -76.14%-36.97%-27.10% Do institutionals & insiders hold more shares of SMMT or ZLAB? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 13.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryZai Lab beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.88B$6.99B$5.68B$8.31BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-12.787.2324.5519.25Price / Sales9.73230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book4.406.617.064.46Net Income-$334.62M$142.13M$3.19B$247.07M7 Day Performance-6.65%2.79%1.49%3.05%1 Month Performance4.39%2.70%5.87%-2.85%1 Year Performance117.85%-4.42%14.94%4.63% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab2.4119 of 5 stars$35.40-0.8%$47.37+33.8%+117.8%$3.88B$398.99M-12.781,950SMMTSummit Therapeutics2.3948 of 5 stars$20.13-3.2%$34.11+69.5%+517.1%$14.85B$700,000.00-71.89110ITCIIntra-Cellular Therapies3.6048 of 5 stars$131.45+0.1%$106.08-19.3%+93.8%$13.98B$680.50M-151.09560Positive NewsGMABGenmab A/S4.0755 of 5 stars$20.80+1.4%$41.33+98.7%-36.4%$13.76B$21.53B11.952,204MRNAModerna4.1065 of 5 stars$34.71+0.3%$59.60+71.7%-69.3%$13.39B$3.20B-3.743,900VTRSViatris1.9959 of 5 stars$9.25+1.6%$10.50+13.5%-24.3%$11.04B$14.74B-12.5037,000RDYDr. Reddy's Laboratories2.9577 of 5 stars$13.23+4.3%$17.00+28.5%-8.3%$11.04B$311.31B21.0624,800Positive NewsGap DownASNDAscendis Pharma A/S3.0905 of 5 stars$168.84+10.4%$202.36+19.9%+11.5%$10.25B$363.64M-23.781,017News CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.5751 of 5 stars$101.35+4.3%$170.41+68.1%-42.5%$9.83B$1.90B81.081,314PCVXVaxcyte2.5198 of 5 stars$75.23+1.2%$147.50+96.1%+8.3%$9.69BN/A-16.35160Positive NewsQGENQiagen4.0456 of 5 stars$39.85+0.9%$47.71+19.7%-4.6%$8.84B$1.98B110.955,967Positive News Remove Ads Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Moderna Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Sarepta Therapeutics Alternatives Vaxcyte Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
